Genetron Covid-19 Test Receives FDA Emergency-Use Authorization
(Bloomberg) --
China-based Genetron Holdings Ltd. announced that it received emergency-use authorization from the U.S. Food and Drug Administration for its Covid-19 detection kits as well as permits from local authorities to export the product.
The virus-detection tests independently developed by Genetron Health, was put in a list of approved Covid-19 reagent manufacturers by the China Chamber of Commerce for Import and Export of Medicines and Health Products, Genetron said Saturday in an emailed statement.
The tests had already received CE marking showing European conformity and other certifications regarding health, safety, and environmental standards for products sold within the European Economic Area.
The Genetron SARS-CoV-2 RNA Test is believed to effectively detect large-scale samples for the novel coronavirus. The features include:
- Enhanced accuracy by detecting two different and highly specific gene sequences of SARS-CoV-2.
- It is quick and easy to operate, can be processed under 2.5 hours and is contamination resistant.
©2020 Bloomberg L.P.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
